IL1R2 and cancer: We excluded patients with infectious diseases,chronic inflammatory diseases or cancer to eliminate the effects of other diseaseprocesses on the association between low levels of sIL-1R2 and adverse outcomes.The major finding in this study was that low levels of sIL-1R2 during the acutephase of AMI were significantly associated with impaired LV contractibilitydefined as a decrease in LVEF ˃10% from hospitalization to 12 months and LVEF<50% at 12 months.